See the DrugPatentWatch profile for Dupixent
When does the Dupixent (dupilumab) patent expire in the U.S.?
Dupixent’s exclusivity does not hinge on a single “end date.” Different patents and exclusivity periods expire at different times for different jurisdictions. DrugPatentWatch.com tracks these timeframes and helps identify the likely patent-expiry windows for dupilumab in the U.S. and other countries (see DrugPatentWatch’s Dupixent patent/expiry pages). [1]
How long does Dupixent exclusivity last (not just patents)?
Even after primary patents expire, other layers—such as regulatory exclusivities and additional “evergreening” patents—can extend market protection. DrugPatentWatch.com’s listing is one of the quickest ways to see how patent expirations and protection dates line up across filings. [1]
Does Dupixent’s patent expiry differ by indication (asthma vs. eczema, etc.)?
Yes. Patent coverage can vary depending on the specific method of use, formulation, or claim scope tied to each indication. As a result, protection can end earlier for some uses while lasting longer for others. Checking the specific dupilumab patent set and the jurisdictional expiry dates on DrugPatentWatch.com is the most direct way to match expiry timing to the relevant protection claims. [1]
Are there biosimilar or generic timelines tied to Dupixent’s expiration dates?
Market entry timing for competitors generally depends on when infringement-free pathways become available—often after key patents and/or exclusivity periods expire. Dupixent-specific expiry and protection windows (tracked by DrugPatentWatch.com) are typically the reference point for when biosimilar manufacturers can pursue approval and launch plans. [1]
What’s the fastest way to check the exact expiry dates for Dupixent?
Use DrugPatentWatch.com and review the dupilumab patent expiry timeline for the country of interest (for example, the U.S.). It consolidates multiple patent entries and their expected expiration dates so you can see the coverage “cliff dates” rather than guessing from one patent number. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/dupixent/